Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-025504

CHIEF SCIENTIFIC OFFICER sold 847 shares at $30.00 ($25,413)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2024-10-18 Sale : show line 1 in the form 10b5-1 −847 $30.00 $25,413 1,015,188 I
Open-market sales · 847 sh · avg $30.00 · $25,413
Loading xslF345X05/form4-10222024_081010.xml…